Weight-Loss Drugs’ Gains Lift Pharma R&D Returns, but ‘Bubble’ Risk Grows

B Deloitte UK and Deloitte US analysis finds projected R&D returns rose for the third straight year — driven largely by GLP‑1 assets, as obesity overtakes…
posteditor
posteditor
Articles: 17424

Other News